Background
Although all tumor, node, metastasis system (TNM) stage IVA papillary thyroid carcinomas (PTCs) do not seem to behave equivalently
as a result of various tumor and node stages, to our knowledge, subclass evaluation has never been attempted.
Methods
We reviewed 119 stage IVA PTC patients who underwent initial thyroidectomy with modified neck dissection as curative surgery
at our institution (33 male patients, 86 female patients; age 61.6 years; follow-up 87.7 months). These patients were divided
into groups A (T1–3N1b; n = 79), B (T4aN0–1a; n = 9), and C (T4aN1b; n = 31). Outcomes were compared between the groups.
Results
The rates of recurrence (P < .05) and disease mortality (P < .001) were 13.9% and 1.3%, 0% and 0%, and 35.5% and 19.4% in groups A, B, and C, respectively. The 10-year disease-free
survival (DFS) and disease-specific survival (DSS) were 73.4% and 97.9%, 100% and 100%, and 54.9% and 69.7% in groups A, B,
and C, respectively. DFS and DSS curves differed significantly between group A + B and group C (P < .005 and P < .0005, respectively). The relative risks of DFS and DSS in group C were 2.8-fold and 14.9-fold, respectively, compared
with group A (P < .05), and 3.2-fold and 17.5-fold compared with group A + B (P < .01). Thus, outcomes were worse in group C. In multivariate analysis, esophageal invasion and lymphadenopathy were independent
risk factors for both DFS and DSS in stage IVA PTC patients.
Conclusions
Outcomes in stage IVA are not equivalent, and patients with T4aN1b are at greater risk for worse prognosis. Therefore, we
recommend subclass evaluation for TNM stage IVA PTCs.
Key Words Papillary thyroid carcinoma - TNM stage IVA - Extrathyroid extension - Lymph node metastasis - Outcome